CA3166307C - Alpha-hydroxylated fatty acid metabolites, medical uses of same and use as biomarkers - Google Patents

Alpha-hydroxylated fatty acid metabolites, medical uses of same and use as biomarkers Download PDF

Info

Publication number
CA3166307C
CA3166307C CA3166307A CA3166307A CA3166307C CA 3166307 C CA3166307 C CA 3166307C CA 3166307 A CA3166307 A CA 3166307A CA 3166307 A CA3166307 A CA 3166307A CA 3166307 C CA3166307 C CA 3166307C
Authority
CA
Canada
Prior art keywords
formula
compound
treatment
dha
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3166307A
Other languages
English (en)
French (fr)
Other versions
CA3166307A1 (en
Inventor
Pablo Vicente Escriba Ruiz
Manuel TORRES CANALEJO
Xavier Busquets Xaubet
Victoria Llado Canellas
Paula FERNANDEZ GARCIA
Catalina Ana ROSSELLO CASTILLO
Sebastia PARETS BARRIOS
Roberto BETETA GOBEL
Emilce CANO URREGO
Laura ARBONA GONZALEZ
Raquel RODRIGUEZ LORCA
Juan CABOT BAUZA
Marc MILLARES PIZA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat de les Illes Balears
Original Assignee
Universitat de les Illes Balears
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES202030070A external-priority patent/ES2846824B2/es
Priority claimed from ES202031155A external-priority patent/ES2911474B2/es
Application filed by Universitat de les Illes Balears filed Critical Universitat de les Illes Balears
Priority to CA3233141A priority Critical patent/CA3233141A1/en
Publication of CA3166307A1 publication Critical patent/CA3166307A1/en
Application granted granted Critical
Publication of CA3166307C publication Critical patent/CA3166307C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3166307A 2020-01-29 2021-01-28 Alpha-hydroxylated fatty acid metabolites, medical uses of same and use as biomarkers Active CA3166307C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3233141A CA3233141A1 (en) 2020-01-29 2021-01-28 Alpha-hydroxylated fatty acids metabolites, medical uses of same and use as biomarkers

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
ESP202030070 2020-01-29
ES202030070A ES2846824B2 (es) 2020-01-29 2020-01-29 Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
EP20382145 2020-02-28
EP20382145.9 2020-02-28
ESP202031155 2020-11-17
ES202031155A ES2911474B2 (es) 2020-11-17 2020-11-17 Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
PCT/ES2021/070068 WO2021152201A2 (es) 2020-01-29 2021-01-28 Metabolitos de ácidos grasos alfa-hidroxilados, usos médicos de los mismos y uso como biomarcadores

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3233141A Division CA3233141A1 (en) 2020-01-29 2021-01-28 Alpha-hydroxylated fatty acids metabolites, medical uses of same and use as biomarkers

Publications (2)

Publication Number Publication Date
CA3166307A1 CA3166307A1 (en) 2021-08-05
CA3166307C true CA3166307C (en) 2024-05-21

Family

ID=77078835

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3166307A Active CA3166307C (en) 2020-01-29 2021-01-28 Alpha-hydroxylated fatty acid metabolites, medical uses of same and use as biomarkers
CA3233141A Pending CA3233141A1 (en) 2020-01-29 2021-01-28 Alpha-hydroxylated fatty acids metabolites, medical uses of same and use as biomarkers

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3233141A Pending CA3233141A1 (en) 2020-01-29 2021-01-28 Alpha-hydroxylated fatty acids metabolites, medical uses of same and use as biomarkers

Country Status (12)

Country Link
US (1) US20230097753A1 (https=)
EP (1) EP4098649A4 (https=)
JP (1) JP7736313B2 (https=)
KR (1) KR20220132552A (https=)
CN (1) CN115052852A (https=)
AU (2) AU2021212330A1 (https=)
BR (1) BR112022015172A2 (https=)
CA (2) CA3166307C (https=)
CL (1) CL2022001985A1 (https=)
IL (1) IL295120A (https=)
MX (1) MX2022009035A (https=)
WO (1) WO2021152201A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3105521A1 (en) 2018-07-20 2020-01-23 F. Hoffmann-La Roche Ag Sulfonimidamide compounds as inhibitors of interleukin-1 activity
ES2982396A1 (es) * 2023-03-14 2024-10-15 Veritas Therapeutics S L 2-hidroxi-octadecen-9-cis-oato para uso en el tratamiento de patologias oncologicas y del dolor neuropatico

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1147221B (de) * 1958-06-28 1963-04-18 Dr Rer Nat Gernot Grimmer Verfahren zur Herstellung von entzuendungs- und oedemhemmenden Salzen der Pentadecen- und Heptadecensaeuren
DE1195296B (de) * 1958-06-28 1965-06-24 Dr Gernot Grimmer Verfahren zur Herstellung von entzuendungs- und oedemhemmenden Salzen der cis-9-Pentadecensaeure und der cis-9-Heptadecensaeure
GB1156465A (en) * 1967-02-16 1969-06-25 Unilever Ltd Prostaglandins
US5856537A (en) 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB9926833D0 (en) * 1999-11-15 2000-01-12 Univ Sunderland Compositions
DE102007055344A1 (de) * 2007-11-19 2009-05-20 K. D. Pharma Bexbach Gmbh Neue Verwendung von Omega-3-Fettsäure(n)
ES2342997B1 (es) * 2008-12-09 2011-06-06 Universitat De Les Illes Balears Alpha derivados de acidos grasos cis-monoinsaturados para ser usados como medicamento.
ES2345241B1 (es) * 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
KR20120065276A (ko) 2009-05-29 2012-06-20 뉴 챕터, 인코포레이티드. 지질 조성을 조정하기 위한 조성물 및 방법
CN102276444B (zh) * 2011-05-04 2013-10-09 厦门大学 脂肪酸类化合物及其制备方法与应用
ES2401629B1 (es) 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.
WO2014113584A1 (en) * 2013-01-16 2014-07-24 Rhode Island Hospital Compositions and methods for the prevention and treatment of osteolysis and osteoporosis
US20150173410A1 (en) * 2013-12-19 2015-06-25 Change Cola, Inc. Beverage comprising omega fatty acid
JP2016222590A (ja) * 2015-05-29 2016-12-28 国立大学法人東京海洋大学 脂肪酸の同位体標識化合物の製造方法およびその方法により得られた脂肪酸の同位体標識化合物、ならびに診断薬
WO2019241728A1 (en) * 2018-06-15 2019-12-19 Youhealth Biotech, Limited Composition and methods for modulation of elovl2

Also Published As

Publication number Publication date
IL295120A (en) 2022-09-01
CA3233141A1 (en) 2021-08-05
JP7736313B2 (ja) 2025-09-09
CN115052852A (zh) 2022-09-13
EP4098649A2 (en) 2022-12-07
US20230097753A1 (en) 2023-03-30
EP4098649A4 (en) 2024-04-17
MX2022009035A (es) 2022-08-11
AU2023248158B2 (en) 2025-11-27
WO2021152201A2 (es) 2021-08-05
AU2021212330A1 (en) 2022-09-22
CA3166307A1 (en) 2021-08-05
CL2022001985A1 (es) 2023-02-03
BR112022015172A2 (pt) 2022-10-11
WO2021152201A3 (es) 2021-09-23
AU2023248158A1 (en) 2023-11-02
KR20220132552A (ko) 2022-09-30
JP2023518640A (ja) 2023-05-08

Similar Documents

Publication Publication Date Title
AU2023248158B2 (en) Alpha-Hydroxylated Fatty-Acid Metabolites, Medical Uses of Same and Use as Biomarkers
JP7025212B2 (ja) 炎症性、変性及び神経変性疾患の治療のための化合物、組成物及び方法
KR101833772B1 (ko) 고도불포화 지방산 유도체의 의약으로서 용도
WO2009052116A1 (en) Methods for treating a variety of diseases and conditions, and compounds useful therefor
CA2929369C (en) Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds
EP3151829A1 (en) Novel sesquiterpene derivatives and their use in inflammation and cancer treatment
WO2014047592A2 (en) Compounds and compositions for use in the prevention and treatment of inflammation-related disorders, pain and fever, skin disorders, cancer and precancerous conditions thereof
WO2004084895A2 (en) Modulation of cell death
JP4649549B2 (ja) グリチルレチン酸誘導体及びその利用
RU2841595C1 (ru) Метаболиты альфа-гидроксилированных жирных кислот, их медицинские применения и применение в качестве биомаркеров
HK40081413A (en) Alpha-hydroxylated fatty-acid metabolites, medical uses of same and use as biomarkers
JP2022500352A (ja) 合成細胞毒性分子、薬剤、それらの合成法および処置法
EP3209637B1 (en) 2-hydroxy-triacylglycerol compounds for use in treating disease
WO2020041051A1 (en) Gemcitabine prodrugs
ES2846824B2 (es) Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos
ES2911474B2 (es) Profarmacos de acidos grasos monoinsaturados y sus metabolitos: usos medicos y como biomarcadores
WO2022079637A1 (en) Analogues of oleuropein and oleacein and uses thereof
Yount et al. A novel camptothecin analog with enhanced antitumor activity
CA3086001A1 (en) Dimers of covalent nfkb inhibitors
Makowskia et al. anorexic side effects
CN111566107A (zh) N-(9,13b-二氢-1H-二苯并[c,f]咪唑并[1,5-a]氮杂卓-3-基)-2-羟基苯甲酰胺及2-((9,13b-二氢-1H-二苯并[c,f]咪唑并[1,5-a]氮杂卓-3-基)氨基甲酰基)苯基乙酸酯的化合物、其制备方法以及包含其的抗炎症及镇痛剂
HK1246271B (zh) 用於合成羟基-三甘油酯的方法及其用於预防和治疗疾病的用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220727

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20250122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250122

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250124

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250124

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250411

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260106

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260106